IP Library Granted Patent US 9,345,720
Granted Patent B2
US 9,345,720 · App. 13/204,228 · Granted May 24, 2016

Composition and method for treating wounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,720
App. No.
13/204,228
Granted
May 24, 2016
Kind
B2
Abstract

Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.

Claims (92)

1. A method of accelerating wound closure in a mammalian subject, the method comprising:

administering topically an effective amount of a water-based formulation to a wound that is selected from the group consisting of incisions, abrasions, lacerations, penetration wounds, burns, ulcerations, surgical wounds, and piercing wounds, the water-based formulation comprising:

an emollient comprising a silicone oil or a petrolatum,

a fatty acid comprising stearic acid,

one or more humectants comprising one or more of a glycerol and a propylene glycol,

one or more emulsifying agents comprising polysorbate 20,

one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers, and

water,

wherein the water-based formulation is formulated as a spray, cream, lotion, milk or foam-former, and

wherein said administrating is for a time sufficient to substantially achieve wound closure.

2. The method of claim 1 , wherein the water-based formulation is applied as a foam using a propellant.

3. The method of claim 1 , wherein the water-based formulation is essentially free of C1 to C6 alcohols but not including polyols.

4. The method of claim 1 , wherein the water-based formulation further comprises a preservative.

5. The method of claim 1 , wherein the water-based formulation is free of preservatives.

6. The method of claim 2 , wherein the water-based formulation must be shaken prior to use.

7. The method of claim 2 , wherein the foam is stable at 35° C. for at least 1 min.

8. The method of claim 1 , wherein the water-based formulation is non-irritating.

9. The method of claim 1 , wherein the water-based formulation is non-sensitizing.

10. The method of claim 1 , wherein the water-based formulation is non-comedogenic.

11. The method of claim 1 , wherein the water-based formulation comprises, by weight % of the composition:

the one or more hydrophilic polymers in an amount in the range of 1.0-3.0%;

stearic acid in an amount in the range of 5.0-8.0%;

propylene glycol in an amount in the range of 4.0-7.0%;

glycerol in an amount in the range of 1.0-2.0%;

dimethicone in an amount in the range of 0.5-5.5%;

triethanolamine in an amount in the range of 0.1-3.0%;

polysorbate 20 in an amount in the range of 1.3-5.0%;

preservative in an amount in the range of 0.0-2.0%; and

water.

12. The method according to claim 1 , wherein the water-based formulation comprises:

0. 5 to 5 weight % of the emollient comprising silicone oil, and

2 to 10 weight % of fatty acid comprising stearic acid.

13. The method according to claim 1 , wherein the water-based formulation further comprises one or more titrants selected from a group consisting of triethanolamine, NaOH, citrate and phosphate.

14. The method according to claim 1 , wherein the administering comprises administering topically the water-based formulation two to three times a day to the wound in an amount of 1 to 5 mg/cm 2 .

15. The method of claim 1 , wherein the administering results in the reduction in the incidence of erythema and/or edema in the wound.

16. The method of claim 1 , wherein the silicone oil is polydimethylsiloxane.

17. The method of claim 1 , wherein the water-based formulation further comprises one or more humectants selected from a group consisting of polyols, excluding glycerol and propylene glycol, polydextrose and lactic acid.

18. The method of claim 1 , wherein the water-based formulation further comprises one or more emulsifying agents selected from a group consisting of sorbital fatty acid esters, octyl glucosides and pegylated lipids.

19. The method of claim 1 , wherein the wound extends the full thickness of the skin.

20. The method of claim 1 , wherein the water-based formulation does not contain an active anti-microbial ingredient.

21. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

one or more titrants; and

water.

22. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

one or more titrants;

one or more preservatives; and

water.

23. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

one or more titrants;

an active agent other than a microbial agent; and

water.

24. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

one or more titrants;

an active agent other than a microbial agent;

one or more preservatives; and

water.

25. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

one or more preservatives; and

water.

26. The method of claim 1 , wherein the water-based formulation consists of:

the emollient comprising the silicone or the petrolatum;

the fatty acid comprising stearic acid;

the one or more humectants comprising one or more of a glycerol and polypropylene glycol;

the one or more emulsifying agents comprising polysorbate 20;

the one or more hydrophilic polymers selected from the group consisting of: polyethylene glycol, starch, cellulose, and carbomers;

an active agent other than a microbial agent; and

water.

Assignments (5)
SECURITY AGREEMENT Recorded Dec 24, 2020
From: RESILIA PHARMACEUTICALS, INC.; PEAK PHARMA COMMERCIAL PARTNERS LLC
To: SG CREDIT PARTNERS
Reel/Frame 054846/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019
From: EXELTIS USA DERMATOLOGY, INC.
To: PARAGON NORDIC AB
Reel/Frame 048828/0504 →
CHANGE OF NAME Recorded Sep 3, 2015
From: QUINNOVA PHARMACEUTICALS, INC.
To: EXELTIS USA DERMATOLOGY, INC.
Reel/Frame 036541/0336 →
CHANGE OF NAME Recorded Jun 1, 2015
From: EVERETT LABORATORIES, INC.
To: EXELTIS USA, INC.
Reel/Frame 035807/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2011
From: HENSBY, CHRISTOPHER N.; SILVANDER, MATS
To: QUINNOVA PHARMACEUTICALS, INC.
Reel/Frame 026995/0854 →